Germline pharmacogenetics of tamoxifen response: Have we learned enough?

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5147-5149

  Desta, Zeruesenay ^a   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; EDITORIAL; ENDOMETRIUM CANCER; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; TAMOXIFEN;

EID: 36849092797     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.4957     Document Type: Editorial

References (22)

1. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
2. Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
3. Stearns V, Ullmer L, Lopez JF, et al: Hot flushes. Lancet 360:1851-1861, 2002
4. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen in relation to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007
5. Jordan VC, Collins MM, Rowsby L, et al: A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 75:305-316, 1977
6. Jordan VC: Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance. Breast Cancer Res Treat 2:123-138, 1982
7. Robertson DW, Katzenellenbogen JA, Long DJ, et al: Tamoxifen antiestrogens: A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13, 1982
8. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317-323, 1982
9. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003
10. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004
11. Lien EA, Solheim E, Kvinnsland S, et al: Identification of 4-hydroxy-Ndesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304-2308, 1988
12. Lim YC, Desta Z, Flockhart DA, et al: Endoxifen (4-hydroxy-N- desmethyltamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478, 2005
13. Lim YC, Li L, Desta Z, et al: Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503-512, 2006
14. Desta Z, Ward BA, Soukhova NV, et al: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075, 2004
15. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
16. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006
17. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
18. Goetz MP, Knox SK, Suman VJ, et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007
19. Nowell SA, Ahn J, Rae JM, et al: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258, 2005
20. Wegman P, Vainikka L, Stål O, et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290, 2005
21. Lim H-S, Lee HJ, Lee ES, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007
22. Bonanni B, Macis D, Maisonneuve P, et al: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxen Trial. J Clin Oncol 24:3708-3709, 2006